Inotuzumab ozogamicin (InO) is a CD22-targeting antibody-drug conjugate (ADC). With its precise targeting and potent cytotoxicity, it has become the first ADC approved globally for relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (R/R B-ALL), and the first and only ADC approved in the field of ALL in China in 60 years. Based on the INO-VATE study, InO received US Food and Drug Administration (FDA) Breakthrough Therapy Designation and Chinese priority review; both the 2026 Chinese Society of Clinical Oncology (CSCO) guidelines and the US National Comprehensive Cancer Network (NCCN) guidelines list InO as a recommended regimen for R/R B-ALL.
As research continues to deepen, the clinical boundaries of InO continue to expand — from later-line salvage for relapsed/refractory disease, to pre-emptive intervention in MRD-positive patients, to induction therapy for elderly or chemotherapy-unfit newly diagnosed patients. Its evidence-based footprint across different stages of B-ALL treatment is becoming increasingly complete. At the 2026 European Hematology Association (EHA) Annual Meeting, three InO-related studies were selected for presentation, building a robust evidence-based chain for full-course management of B-ALL. In this context, MedJ invited Prof. Ying Wang of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS) — the lead investigator of these studies — to systematically interpret the research rationale and key data, and to share her insights on the positioning and prospects of InO in full-course B-ALL management.
About the Expert — Prof. Ying Wang
·Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS)
·Director, Immune Cell Therapy Center & International Diagnosis and Treatment Center
·Chief physician, MD, doctoral supervisor
·National Health System Advanced Worker; Tianjin Medical Talent
·Standing Committee member and Secretary-General, Leukemia Expert Committee, Chinese Society of Clinical Oncology (CSCO)
·Lead, Leukemia Immune Cell Therapy Collaborative Group, China Hematology Specialty Alliance
·Standing Committee member, Sixth Hematologic Oncology Committee, China Anti-Cancer Association
·Standing Committee member, Leukemia Branch, China Medical Education Association
·Member, Cell and Gene Therapy Branch, Chinese Society for Cell Biology
·Member, Hematologic Disease Rehabilitation Committee, Chinese Rehabilitation Medicine Association
·Vice Chair, Council of Tianjin Society of Hematology and Regenerative Medicine
·Editorial board member, Chinese Journal of Hematology and Journal of Leukemia & Lymphoma
·Postdoctoral fellow, Winship Cancer Institute, Emory University, United States
·Main research focus: clinical and basic research on leukemia and immune cell therapy
Q1. At this year’s EHA, you have three InO-related studies selected for presentation, covering the full B-ALL continuum from frontline induction to MRD clearance to relapse salvage. As the lead investigator of multiple InO-related studies, could you share the unmet clinical needs behind these studies, and the thinking and original intent behind launching this series of research?
Prof. Wang:
The reason we designed separate clinical trials at different stages of B-ALL treatment lies in unmet clinical needs.
In the induction treatment stage of newly diagnosed patients, what we pursue is not only hematologic remission, but also achieving deeper high-quality remission — enabling more patients in remission to achieve early MRD negativity. Because prior research has confirmed that early achievement of MRD negativity in induction remission is a favorable factor for improved survival outcomes [1].
In the consolidation stage, some patients remain MRD-positive or repeatedly convert back to MRD-positive — detectable MRD often predicts a higher risk of relapse. For these patients, we designed a single-arm prospective study of InO for MRD clearance, to confirm its strong residual-disease-eradicating ability.
In addition, even with extensive standard treatment, relapsed/refractory disease cannot be fully avoided, and the high cost of CAR-T therapy is unaffordable for many, leaving even greater unmet needs in this population. Therefore, we hope that in the real world, by exploring different antibody-drug combination regimens, we can build on single-agent efficacy to further improve benefit and reduce toxicity.
Q2. One of the studies presented at EHA (Abstract PF380) is a Phase 2 study of the AVCDV regimen — venetoclax combined with InO and reduced chemotherapy — which has achieved encouraging efficacy and safety in older or chemotherapy-unfit newly diagnosed Ph-negative B-ALL patients. How do you interpret these data, and what is the impact on clinical practice?
Prof. Wang:
This study targets exactly the elderly and chemotherapy-unfit patients — traditional intensive chemotherapy is too toxic for them, but reducing intensity raises concerns about insufficient efficacy. The design rationale of AVCDV is: with chemotherapy as the foundation, after adding InO and a BCL-2 inhibitor, we have the basis to reduce chemotherapy dose to lessen adverse reactions.
Why choose InO as the core of immunotherapy? The INO-VATE study has already confirmed that InO monotherapy achieved a CR/CRi rate of 80.7% in R/R patients, and tumor burden has relatively little impact on efficacy [2]. Newly diagnosed patients often have high tumor burden, so using InO in the induction stage is the better immunotherapy choice.
This study enrolled 36 newly diagnosed Ph-negative B-ALL patients, with a median age of 55 years and a median bone marrow blast proportion of 81.5%, and a high proportion of high-risk cytogenetic abnormalities (TP53 mutation 30.6%, KMT2A rearrangement 13.9%, IKZF1 abnormality 13.9%, etc.). Preliminary data show a CR rate of 97.2% and a day-28 flow MRD-negative rate of 82.9% [3]. More importantly, we subsequently modified the protocol: if MRD is still positive on day 14 of induction, an additional dose of InO is given. We believe MRD conversion rates will further improve.
In terms of safety, in these elderly, unfit, and high-tumor-burden patients, no treatment-related deaths occurred with the AVCDV regimen, successfully avoiding the severe infections, organ failure, and other complications common with traditional intensive chemotherapy, providing these fragile patients with a truly “high-efficacy, low-toxicity” treatment option.
Q3. Another study (Abstract PF376) focuses on patients whose MRD has not converted to negative or who have MRD re-emergence after first-line treatment, using a 1-2 cycle InO regimen. How do you evaluate this treatment strategy? What is the significance of completing the full 2 cycles in a standardized manner?
Prof. Wang:
InO was first used in the INO-VATE study for R/R patients, where the protocol allowed up to 6 cycles after remission. However, in the real world, constrained by financial pressures and patients’ own conditions, most patients have difficulty completing 6 cycles of continuous treatment. Therefore, our design rationale is: through a relatively short course of treatment, achieve the deepest possible remission as a solid foundation of high-quality remission for subsequent treatment — whether bridging to transplant or consolidation chemotherapy. The protocol allows up to 2 cycles, and in practice, most patients achieve MRD negativity after just 1 cycle, with only a few requiring 2 cycles —
The study enrolled 31 patients in first complete remission (CR1) with MRD positivity (flow MRD ≥0.01%), with high-risk molecular features including Ph-like (5 cases), ZNF384 fusion (11 cases), IKZF1 alteration (9 cases), TP53 mutation (2 cases). Results showed that 87% of patients achieved MRD negativity after cycle 1; the remaining 3 MRD-positive patients (2 carrying ZNF384 fusion, 1 with IKZF1 alteration) all successfully converted after cycle 2, for an overall MRD clearance rate of 97% [4].
It is worth emphasizing that, for patients in high-risk cytogenetic subgroups, MRD may still be positive after 1 cycle, but the 2-cycle treatment delivers deep remission — this shows that standardized completion of 2 cycles remains critical for high-risk patients.
In terms of safety, no SOS/VOD events were reported in this study, including in patients who subsequently bridged to transplant. Overall, moving InO forward into the CR1 stage for MRD clearance has changed the previous passive pattern of “waiting for relapse before salvage,” giving MRD-positive patients the opportunity to eradicate minimal residual disease during remission and fight for long-term survival.
Q4. Another Chinese Phase 4 study (Abstract PB2613) provides the longest domestic follow-up data for InO in R/R B-ALL, with a median OS of 23.1 months. How do you view the therapeutic value of InO in this population?
Prof. Wang:
From the INO-VATE study onward, the efficacy of InO has been fully confirmed — this is also the basis on which it successfully received marketing approval and changed the R/R B-ALL treatment landscape. This Chinese Phase 4 study fully followed the INO-VATE treatment regimen, using domestic data to once again validate the reliable efficacy of InO in Chinese patients — a solid landing from global to China.
The study enrolled 44 adult Chinese R/R B-ALL patients, with a median age of 45 years, 25% Ph-positive, and 47.7% having previously received second-line salvage therapy. At a median follow-up of 23.9 months, the CR/CRi rate was 81.8%, with rapid response — a median time to response of 0.72 months, median OS of 23.1 months, and 2-year OS rate of 48.8%. In both response rate and survival benefit, the Chinese data remain highly consistent with the INO-VATE study, and even showed a trend toward greater benefit in OS and progression-free survival (PFS). It is worth noting that the median treatment was about 4 cycles; this standardized full-course treatment is also a key factor in achieving long-term survival.
Safety is equally reassuring — in this study, the SOS/VOD incidence was only 4.5%, numerically lower than the 11% in global studies, with no new safety signals. Overall, both the survival and safety data from the Chinese Phase 4 study give us more confidence in the clinical use of InO.
Summary and Outlook
From INO-VATE to the three EHA studies, the evidence-based journey of InO has expanded from later-line to frontline, from monotherapy to combination, and has solid landed from global validation to the Chinese population, together outlining the broad application prospects of this ADC in B-ALL: in the frontline stage, combination with reduced chemotherapy and targeted agents can achieve “high-efficacy, low-toxicity” induction; in the consolidation stage, short-course MRD clearance can create opportunities for deep remission and long-term survival in high-risk patients; in the salvage stage, single-agent full-course treatment can also deliver durable survival benefit.
Looking ahead, more real-world research is expected to accumulate clinical experience, advance the implementation of standardized treatment, and continuously enrich the evidence base and refine clinical practice — ultimately achieving the dual goals of deep remission and long-term survival in a broader patient population and truly changing the treatment landscape of B-ALL.
References
[1] Walid Macaron, et al. Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular Features. Blood 2024; 144 (Supplement 1): 727.
[2] Kantarjian HM, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016 Aug 25;375(8):740-53.
[3] Gu RX, et al. EFFICACY AND GENETIC CORRELATES OF VENETOCLAX-BASED IMMUNOCHEMOTHERAPY IN OLDER/UNFIT B-ALL: A PHASE 2 STUDY IN THE ERA OF NOVEL COMBINATIONS: RESULTS A PHASE 2 MULTI-CENTER CLINICAL TRIAL. EHA 2026 Abstract PF380.
[4] Gu RX, et al. EARLY USE OF INOTUZUMAB OZOGAMICIN IN FIRST REMISSION ACHIEVES DEEP AND DURABLE MRD ERADICATION IN ADULTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE B-ALL: A PROSPECTIVE PHASE II STUDY. EHA 2026 Abstract PF376.
[5] Wu DP, et al. EFFICACY AND SAFETY OF INOTUZUMAB OZOGAMICIN IN ADULT CHINESE PATIENTS WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKOSIS: LONG-TERM RESULTS OF AN OPEN-LABEL, MULTI-CENTER, PHASE 4 TRIAL. EHA 2026 Abstract PB2613.